You might also like
LifeMD, Inc. (LFMD) is a direct-to-patient telehealth company that simplifies healthcare by providing virtual and in-home medical services. The company offers subscription-based access to licensed healthcare professionals and delivers prescription medications, over-the-counter products, and digital solutions. LFMD also operates a SaaS platform for document management.
-
Telehealth - Provides virtual healthcare services, including primary care, chronic disease management, and lifestyle treatments such as weight management, sleep, hair loss, hormonal therapy, and sexual health. Offers prescription and OTC products through a subscription model.
- ShapiroMD - Offers hair loss treatments, including FDA-approved minoxidil and an FDA-cleared medical device.
- RexMD - Focuses on men’s health, offering treatments for erectile dysfunction, premature ejaculation, and hair loss.
- NavaMD - Provides tele-dermatology and skincare solutions for women.
- GLP-1 Weight Management Program - Includes prescriptions for GLP-1 medications, lab work, primary care, and holistic coaching.
-
WorkSimpli - Operates PDFSimpli, a SaaS platform for converting, signing, editing, and sharing PDF documents, generating recurring revenue through subscription services.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Justin Schreiber ExecutiveBoard | Chief Executive Officer | Justin Schreiber has served as the Chief Executive Officer of LifeMD since 2018 and as Chairman of the Board since 2019. He brings extensive expertise in healthcare, capital markets, and investor relations, playing a pivotal role in the company’s strategic growth. | View Report → | |
Dennis Wijnker Executive | Chief Technology Officer (CTO) | Dennis Wijnker is the Chief Technology Officer at LifeMD, Inc. since December 2021. He previously held senior roles at Doctor Evidence and Parexel/Perceptive Informatics, where he contributed significantly to technology innovation in healthcare. | ||
Jessica Friedeman Executive | Chief Marketing Officer | Jessica Friedeman has served as the Chief Marketing Officer at LifeMD, Inc. since January 2023. She brings nearly 20 years of marketing expertise, previously holding executive roles at Mercury Healthcare, Healthgrades, and Evariant. | ||
Marc Benathen Executive | Chief Financial Officer (CFO) | Director of the Baruch College Alumni Association | Marc Benathen has been serving as the CFO of LifeMD, Inc. since February 2021. He brings over 18 years of experience in financial management and previously served as CFO of Blink Holdings, Inc. from 2017 until January 2021. | |
Dr. Joan LaRovere Board | Independent Director | Co-Founder and Vice President at Virtue Foundation; Director of Innovation and Outcomes and Senior Staff Physician at Boston Children’s Hospital; Assistant Professor of Pediatrics at Harvard Medical School; Professional Advisor at Martin Trust Center for MIT Entrepreneurship; Healthcare Operating Partner at iSelect Fund | Dr. Joan LaRovere has served as an Independent Director at LifeMD, Inc. since February 9, 2023, contributing deep expertise in healthcare innovation and leadership. She has held active roles in healthcare and academia at Virtue Foundation, Boston Children's Hospital, Harvard Medical School, and other organizations. | |
Roberto Simon Board | Board Member and Chairman of the Audit Committee | CFO of Norstella | Roberto Simon is a board member and the Chairman of the Audit Committee at LFMD, recognized as an audit committee financial expert. He joined LFMD's board in 2020 and renewed his director agreements in July 2022, August 2023, and December 2024. | |
William J. Febbo Board | Director | Faculty Member, MIT linQ Program; Board Member, United Nations of Greater Boston | William J. Febbo has served as a Board Director of LifeMD since June 2023 and entered into a consulting services agreement on May 30, 2023 to provide investor relations and strategic business development services. | |
Brad Roberts | Advisor | Brad Roberts served as the Chief Operating Officer of LFMD from December 2020 until his mutual separation on March 8, 2024, and now continues as an advisor. He brings over 16 years of executive experience in direct-to-consumer, FinTech, and healthcare companies. |
-
Given your efforts to transition patients from compounded therapies to branded GLP‑1 medications, how do you plan to mitigate the risk if prior authorization approval rates, even after recent improvements, begin to falter in a more competitive market?
-
You highlighted an 18 percentage point increase in prior authorization approvals for branded GLP‑1 between October and January; what are the key drivers behind that improvement, and how sustainable are they in the face of evolving regulatory and insurance dynamics?
-
With the onboarding of your new pharmacy causing a temporary drop in gross margins, can you detail the specific measures being implemented to normalize margins back to the targeted 88%–90% range and any lingering cost issues that might affect this trajectory?
-
You mentioned that remote patient monitoring via wearables is not on the roadmap for 2025; what are the main challenges or strategic reasons behind this decision, and could delaying this development compromise LifeMD’s competitive edge in virtual care?
-
Your guidance assumes a mid-single-digit revenue contribution from new insured lives in 2025, with expectations to reach 30%–50% in a few years; what operational or market challenges do you foresee in scaling these insurance offerings, and what contingencies are in place if growth stalls?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
ResumeBuild | 2022 | In February 2022, WorkSimpli (a majority-owned subsidiary of LifeMD) acquired ResumeBuild for $4.0M upfront plus a contingent consideration of at least $500K, securing all assets related to its subscription-based resume-building SaaS platform; the deal was financed through a promissory note and structured as an asset acquisition under ASC 805 to bolster WorkSimpli’s transformation. |
Cleared Technologies PBC | 2022 | Completed on January 18, 2022, LifeMD acquired Cleared Technologies, a nationwide allergy telehealth platform, with an initial payment of $460K at closing, two subsequent installments of $1.73M each, and a potential earn-out up to $72.8M tied to revenue milestones; the deal’s flexible payment options (cash/stock) and escrow arrangement supported LifeMD’s expansion into direct-to-patient telehealth services in allergy, asthma, and immunology. |
Recent press releases and 8-K filings for LFMD.
- Marcum LLP resigned as LifeMD’s independent registered public accounting firm on April 24, 2025, and the company has engaged CBIZ CPAs P.C. as its new auditor, following Marcum’s departure after serving since 2022.
- The transition was approved by the Audit Committee, with previous financial statements for 2023 and 2024 having been reported without adverse opinions or modifications.
- Consolidated revenue reached $64.3 million in Q4 2024, driven by a 60% jump in telehealth revenue.
- Adjusted EBITDA increased 78% to $9.0 million; telehealth adjusted EBITDA of $5.9 million and WorkSimpli’s monthly adjusted EBITDA over $1M supported robust operational performance.
- Provided 2025 guidance with expected revenue between $265M-$275M (including a forecast of $270M with 27% growth) and adjusted EBITDA between $30M-$32M, alongside Q1 2025 revenue projections of $61M-$63M.
- GAAP net loss improved to $883,000 from $4.5 million year-over-year, reflecting strong cost management.
- Showcased a comprehensive virtual healthcare platform offering virtual primary care and telemedicine services, supported by a 50-state affiliated medical group.
- Advanced strategic initiatives in DTC telemedicine, virtual primary care, and B2B solutions while launching new offerings including LifeMD+ and behavioral health services.